Researchers have identified SIRT1 as a promising new target in neuroendocrine prostate cancer, a rare but highly aggressive subtype that often develops after standard hormone therapy stops working. The finding is important because this form of prostate cancer is especially hard to treat and tends to behave more aggressively than typical androgen-driven disease. The study […]
YL201, a B7-H3–targeting antibody–drug conjugate, is showing notable activity in advanced metastatic castration-resistant prostate cancer (mCRPC), including patients who have progressed after androgen receptor–targeted therapy and chemotherapy. In a phase 2 study of 82 heavily pretreated patients, the drug delivered a confirmed PSA50 response rate of 38.5%, an objective response rate of 29.5%, and a […]
A Phase 1b/2 trial is planned to test the investigational KAT6 inhibitor OP-3136 combined with darolutamide in metastatic castration-resistant prostate cancer (mCRPC). About 36 patients will be enrolled, with the study expected to start in the second half of 2026. The focus is on safety, tolerability, and early signs of anti-tumor activity. OP-3136 blocks KAT6A/B, […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! This week we have a solid set of clinical trials and retrospective studies. We are making progress day by day. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the […]
A new phase 2 study, A-DREAM / Alliance A032101, suggests that a carefully selected group of men with metastatic hormone-sensitive prostate cancer may be able to interrupt androgen deprivation therapy and an androgen receptor pathway inhibitor after achieving an excellent response, while still maintaining a treatment-free interval. The study met its primary endpoint, with 41% […]
The TALENT trial is a randomized, open‑label, phase 2 trial evaluating whether adding enzalutamide to talazoparib improves outcomes compared with talazoparib alone in men with metastatic castration‑resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) gene alterations and have progressed after abiraterone‑based therapy. The trial builds on the phase 3 TALAPRO‑2 results, which showed […]
ABBV-969, a first-in-class dual-targeting antibody-drug conjugate (ADC), is emerging as a promising new therapeutic candidate for patients with metastatic castration-resistant prostate cancer (mCRPC), particularly in the late-line setting where treatment options are limited and outcomes remain poor. Designed to simultaneously target prostate-specific membrane antigen (PSMA) and six-transmembrane epithelial antigen of prostate 1 (STEAP1), both highly […]
Actinium-225 rosopatamab tetraxetan (CONV01-α) is a PSMA-targeted alpha radioligand therapy being tested in men with metastatic castration-resistant prostate cancer who have already received androgen receptor pathway inhibitors, up to one taxane regimen, and 1–6 cycles of lutetium-177 PSMA therapy (Pluvicto), with all patients having PSMA PET–positive disease by VISION criteria. The drug links an alpha […]
A new investigational drug, HRS-5041, may offer a compelling strategy to overcome resistance to androgen receptor (AR)-targeted therapies.. Unlike traditional AR inhibitors, HRS-5041 is an oral androgen receptor degrader designed to eliminate the receptor itself, including clinically relevant mutant forms. In a phase 1, 156 patients with mCRPC were treated with HRS-5041. All patients had […]
Bipolar androgen therapy (BAT) given before sipuleucel‑T appears to increase the rate and magnitude of PA2024‑specific immune responses in men with metastatic castration‑resistant prostate cancer (mCRPC), compared with historical sipuleucel‑T data. The central interpretation is not that BAT by itself generates this immune response, but that BAT may prime the tumor and immune environment so […]